AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Close
Create a link to this page
Copy and paste this link tag into your Web page or blog:
<a href="http://www.accessmylibrary.com/coms2/summary_0286-26126822_ITM" title="Facts and information about JAPAN'S CHUGAI FORMS ANTIBODY DRUG DEVELOPMENT TIE-UP WITH U.K. FIRM.">JAPAN'S CHUGAI FORMS ANTIBODY DRUG DEVELOPMENT TIE-UP WITH U.K. FIRM.</a>
Close
Set up an RSS feed that alerts you when new articles from AsiaPulse News are available.
Frequently asked questions about RSS feeds
JAPAN'S CHUGAI FORMS ANTIBODY DRUG DEVELOPMENT TIE-UP WITH U.K. FIRM.
TOKYO, Oct 1 Asia Pulse - Chugai Pharmaceutical Co. (TSE:4519) announced Monday that it has formed a partnership with U.K. bioventure Cambridge Antibody Technology Ltd., or CAT, to develop antibody drugs.
Under the agreement, Chugai will use CAT's technology for highly efficient production of antibodies in its own efforts to develop new antibody drugs.
Antibody drugs ...
Related articles from newspapers, magazines, journals, and more
For more facts and information, see all results
- Cambridge Antibody Technology and AMRAD Corporation Limited Form Alliance for...
- Press release article from: PR Newswire December 19, 2001 700+ words
...MELBOURN, England and MELBOURNE, Australia -- Cambridge Antibody Technology and AMRAD Corporation Limited today...great commercial results." Notes to Editors: Cambridge Antibody Technology (CAT) * CAT is a UK biotechnology...
- Cambridge Antibody Technology Group plc Preliminary Statement of Results For...
- Press release article from: PR Newswire November 26, 2001 700+ words
...growing pipeline of new antibody drugs." CAT secured seven...risks of developing antibody drugs and, in turn, sharing...of clinical grade antibody drugs for up to five years...formation in 1990 Cambridge Antibody Technology has grown...
- Cambridge Antibody Technology Group plc 2002 Annual General Meeting Statement.
- Press release article from: PR Newswire February 1, 2002 700+ words
...pipeline of new antibody drugs. CAT will also...Garland, Chairman, Cambridge Antibody Technology Group...Notes to Editors: Cambridge Antibody Technology (CAT...Communications, all of Cambridge Antibody Technology...
- Cambridge Antibody Technology and Lonza Biologics Announce Long Term Supply...
- Press release article from: PR Newswire November 26, 2001 700+ words
...PRNewswire/ -- Cambridge Antibody Technology (Nasdaq...clinical grade antibody drugs to CAT for up to...agreement." Notes: Cambridge Antibody Technology (CAT...statements about Cambridge Antibody Technology Group...
- Cambridge Antibody Technology and Searle Form Major Drug Development Alliance...
- Press release article from: PR Newswire December 24, 1999 700+ words
...PRNewswire/ -- Cambridge Antibody Technology ("CAT...development of human antibody drugs with Searle's...of fully-human antibody drugs and the high-throughput...Ulysses Group. Cambridge Antibody Techno
- Cambridge Antibody Technology Announces Preliminary Statement of Results for...
- Press release article from: PR Newswire November 17, 2003 700+ words
Cambridge Antibody Technology Group plc...of human monoclonal antibody drugs, and likely to be...Company every success." CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc...of human monoclonal antibody drugs, and likely to be...
- Cambridge Antibody Technology Group plc 2004 Annual General Meeting Statement.
- Press release article from: PR Newswire January 30, 2004 700+ words
...Annual General Meeting of Cambridge Antibody Technology Group plc being...and supply clinical grade antibody drugs to CAT through to the end...goals". Notes to Editors Cambridge Antibody Technology (CAT): * CAT...
- Cambridge Antibody Technology Group plc Preliminary Statement of Results for...
- Press release article from: PR Newswire November 27, 2000 700+ words
...pharmaceutical and genomics companies." CAMBRIDGE ANTIBODY TECHNOLOGY GROUP plc Preliminary Statement...validation and the development of antibody drugs. To maximise the commercial opportunities...there were more human monoclonal antibody drugs in clinical development derived by...
Source: HighBeam Research, JAPAN'S CHUGAI FORMS ANTIBODY DRUG DEVELOPMENT TIE-UP WITH U.K. FIRM.